Clinical Efficacy of Injection and Mechanical Therapy for Peyronie's Disease: A Systematic Review of the Literature

被引:39
作者
Russo, Giorgio Ivan [1 ]
Milenkovic, Uros [2 ]
Hellstrom, Wayne [3 ]
Levine, Laurence A. [4 ]
Ralph, David [5 ,6 ]
Albersen, Maarten [2 ]
机构
[1] Univ Catania, Dept Surg, Urol Sect, Catania, Italy
[2] Univ Hosp Leuven, Dept Urol, Leuven, Belgium
[3] Tulane Univ, Sch Med, Dept Urol, New Orleans, LA 70112 USA
[4] Rush Univ, Med Ctr, Dept Urol, Chicago, IL 60612 USA
[5] Univ Coll London Hosp, St Peters Androl Ctr, London, England
[6] Univ Coll London Hosp, Inst Urol, London, England
关键词
Collagenase Clostridium histolyticum; Hyaluronic acid; Interferon alpha-2b; Intralesional therapy; Penile curvature; Penile traction; Peyronie's disease; Vacuum device; Verapamil; COLLAGENASE CLOSTRIDIUM-HISTOLYTICUM; INTRALESIONAL VERAPAMIL INJECTION; PENILE TRACTION THERAPY; HYALURONIC-ACID; DOUBLE-BLIND; INTRAPLAQUE INJECTION; PREDICTIVE FACTORS; SINGLE-CENTER; SAFETY; INTERFERON-ALPHA-2B;
D O I
10.1016/j.eururo.2018.07.005
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
Context: Conservative therapies for Peyronie's disease (PD) aim to treat early-stage disease by improving clinical outcomes such as penile curvature, penile length erectile dysfunction, and pain. Objective: To summarise the available evidence regarding injection and mechanical therapies for PD treatment. Evidence acquisition: An extensive search of Medline, Embase, and Scopus databases retrieved English-language articles up to 15 May 2018. The systematic review protocol was registered on PROSPERO (CRD42017077050). Inclusion criteria were as follows: adults with early or chronic PD receiving treatment with injection therapy, penile traction, or a vacuum device. Evidence synthesis: Fifty-two articles were selected according to the inclusion criteria-17 comparative studies and 35 cohort studies-analysing the effects of calcium channel blockers (verapamil, nicardipine), collagenase Clostridium histolyticum (CCH), interferon alpha-2b (IFN alpha-2b), hyaluronic acid (HA), onabotulinum toxin A, thiocolchicine, penile extender devices, and vacuum devices. Qualitative data from these studies suggest a clinically significant effect of CCH and IFNa-2b injection therapy to decrease penile curvature and conserve penile length. Verapamil and HA performed well in single-arm or case-control studies. Studies of penile traction and vacuum devices in patients with PD demonstrated some benefits in terms of curvature and penile length but only in small, underpowered, nonrandomised studies. Studies of onabotulinum toxin A injections or thiocolchicine showed significant improvements in penile curvature, but only in studies of single-arm or case-control design. Conclusions: CCH and IFNa-2b injected into stable PD plaques can decrease penile curvature; CCH can also improve penile length. However, based on available data, strong conclusions cannot be drawn for other treatments, including calcium channel blockers, HA, or mechanical therapies. Patient summary: Our systematic review of injection therapies provides evidence for improvements in penile curvature for patients with Peyronie's disease. No robust evidence is available to support the use of other local treatments including calcium channel blockers, hyaluronic acid, or mechanical therapies. (C) 2018 European Association of Urology. Published by Elsevier B.V. All rights reserved.
引用
收藏
页码:767 / 781
页数:15
相关论文
共 65 条
[1]   Combination of Penile Traction, Intralesional Verapamil, and Oral Therapies for Peyronie's Disease [J].
Abern, Michael R. ;
Larsen, Stephen ;
Levine, Laurence A. .
JOURNAL OF SEXUAL MEDICINE, 2012, 9 (01) :288-295
[2]  
Ahuja S, 1999, J ANDROL, V20, P444
[3]   Impact of Number of Cycles of Collagenase Clostridium Histolyticum on Outcomes in Patients With Peyronie's Disease [J].
Anaissie, James ;
Yafi, Faysal A. ;
DeLay, Kenneth J. ;
Traore, Elizabeth J. ;
Sikka, Suresh C. ;
Hellstrom, Wayne J. G. ;
Hellstrom, G. .
UROLOGY, 2017, 100 :125-130
[4]  
Muñoz-Rangel CA, 2015, UROL J, V12, P2105
[5]  
Astorga R, 2000, Arch Esp Urol, V53, P665
[6]   Intralesional verapamil prevents the progression of Peyronie's disease [J].
Bennett, Nelson E. ;
Guhring, Patricia ;
Mulhall, John P. .
UROLOGY, 2007, 69 (06) :1181-1184
[7]   Treatment of Peyronie's disease with local interferon-α 2b [J].
Brake, M ;
Loertzer, H ;
Horsch, R ;
Keller, H .
BJU INTERNATIONAL, 2001, 87 (07) :654-657
[8]   Analysis of the clinical safety of intralesional injection of collagenase Clostridium histolyticum (CCH) for adults with Peyronie's disease (PD) [J].
Carson, Culley C., III ;
Sadeghi-Nejad, Hossein ;
Tursi, James P. ;
Smith, Ted M. ;
Kaufman, Gregory J. ;
Gilbert, Kimberly ;
Honig, Stanton C. .
BJU INTERNATIONAL, 2015, 116 (05) :815-822
[9]   Open preliminary randomized prospective clinical trial of efficacy and safety of three different verapamil dilutions for intraplaque therapy of Peyronie's disease [J].
Cavallini, Giorgio ;
Modenini, Fablo ;
Vital, Giovanni .
UROLOGY, 2007, 69 (05) :950-954
[10]   Predictive Factors of Patients' and Their Partners' Sexual Function Improvement After Collagenase Clostridium Histolyticum Injection for Peyronie's Disease: Results From a Multi-Center Single-Arm Study [J].
Cocci, Andrea ;
Russo, Giorgio Ivan ;
Salonia, Andrea ;
Cito, Gianmartin ;
Regis, Federica ;
Polloni, Gaia ;
Giubilei, Gianluca ;
Cacciamani, Giovanni ;
Capece, Marco ;
Falcone, Marco ;
Greco, Isabella ;
Timpano, Massimiliano ;
Minervini, Andrea ;
Gacci, Mauro ;
Cai, Tommaso ;
Garaffa, Giulio ;
Giammusso, Bruno ;
Arcaniolo, Davide ;
Mirone, Vincenzo ;
Mondaini, Nicola .
JOURNAL OF SEXUAL MEDICINE, 2018, 15 (05) :716-721